Skip to main content
Article thumbnail
Location of Repository

Evidence of comparative efficacy should have a formal role in European drug approvals

By Corinna Sorenson, Huseyin Naci, Jonathan Cylus and Elias Mossialos

Abstract

Despite methodological concerns, comparative efficacy evidence should be required at the time of drug approval, says Corinna Sorenson and colleagues, to allow patients, clinicians, and other healthcare decision makers to determine whether a new drug is superior, equivalent, or inferior to its existing alternatives

Topics: RA Public aspects of medicine, RM Therapeutics. Pharmacology
Publisher: BMJ Publishing Group
Year: 2011
DOI identifier: 10.1136/bmj.d4849
OAI identifier: oai:eprints.lse.ac.uk:38191
Provided by: LSE Research Online

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.